Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213643 | 0.83 | CCR2 (0.34) | — | |
| SCHEMBL13784844 | 0.82 | GABRR1 (0.31) | — | |
| SCHEMBL15943103 | 0.82 | OPRD1 (0.31) | — | |
| SCHEMBL8250376 | 0.79 | GSK3B (0.33) | — | |
| SCHEMBL12816825 | 0.79 | SLC6A3 (0.33) | — | |
| SCHEMBL13149375 | 0.79 | OPRD1 (0.30) | — | |
| SCHEMBL8245630 | 0.78 | CHRNB2 (0.30) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL17733597 | 0.78 | CHRNB2 (0.30) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL13249008 | 0.78 | CHRNB2 (0.30) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL14369479 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20120045459-A1 | Methods for Treating Autophagy-Related Disorders | VAN ANDEL RESEARCH INSTITUTE (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2007048943-A1 | HETEROGENEOUS CATALYST SYSTEM AND THE USE THEREOF | NOVALYST DISCOVERY (FR) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045459-A1 | Methods for Treating Autophagy-Related Disorders | ATG7, MTMR1, BECN1 | CHRNB2 1175/4885CHRNA7 2224/4885CHRNA4 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.